Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

1. The manufacturing challenges facing the viral vector industry
2. The advantages of an integrated manufacturing solution
3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom